Prostate Cell News 10.27 July 26, 2019 | |
| |
TOP STORYGene Test Picks Out Prostate Cancer Patients Who Could Benefit from ‘Search-and-Destroy’ Medicine Testing for genetic weaknesses in repairing DNA could pick out men who may benefit from a new type of targeted nuclear medicine. Scientists at The Institute of Cancer Research, London, found that testing men for faults in DNA repair genes in their tumors could identify those most likely to respond to a new type of treatment. [Institute of Cancer Research] Press Release | Full Article | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Researchers crossed a transgenic prostate adenocarcinoma mouse model, Hi-Myc mice, with a liver-specific insulin-like growth factor-1 (IGF-1) transgenic mouse model to increase their circulating IGF-1 levels to investigate the impact of the elevated circulating IGF-1 on prostate cancer development in vivo. [Oncogene] Abstract In C4-2B MDVR cells, degarelix alone or combined with abiraterone or enzalutamide reduced AR-V7 protein expression compared to the control group. SCID mice bearing VCaP xenograft tumors were divided into four groups and treated with surgical castration, degarelix, leuprolide or buffer alone for four weeks. [Mol Cancer Ther] Abstract Androgen receptor (AR)-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. [Sci Rep] Full Article Low Expression of miR-424-3p Is Highly Correlated with Clinical Failure in Prostate Cancer The clinical significance of miR-424-3p expression in prostate cancer tissue was evaluated. Naïve radical prostatectomy specimens from 535 patients was used for tissue microarray construction. [Sci Rep] Full Article Using high-throughput liquid chromatography-high definition mass spectrometry combined with pattern recognition methods was performed to analyze the cell metabolic profiles and pathway of obacunone on prostate cancer. [J Proteomics] Abstract T-Type Calcium Channels Drive the Proliferation of Androgen-Receptor Negative Prostate Cancer Cells Investigators evaluated T-type calcium channel expression in a panel of prostate cancer cell lines and measured the effect of their inhibition on cell proliferation and survival using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and caspase assays. [Prostate] Abstract Higher glucocorticoid receptor (GR) levels, but lower androgen receptor levels were detected in radioresistant cells than in parental cells. Radiation-induced GR upregulation was associated with increased intracellular cyclic adenosine monophosphate. [Prostate] Abstract Effect of Polyunsaturated Fatty Acids on Proliferation and Survival of Prostate Cancer Cells Scientists showed that hormone-dependent cells were comparatively insensitive to various polyunsaturated fatty acids (PUFAs), at the same time as the growth and viability of hormone-independent cells lines were strongly inhibited by most of the tested PUFAs. [PLoS One] Full Article Paxillin Regulated Genomic Networks in Prostate Cancer Paxillin enhanced several pro-proliferative pathways, including the CyclinD/Rb/E2F and DNA replication/repair pathways. Additionally, paxillin suppressed pro-apoptotic genes, including CASP1 and TNFSF10. [Steroids] Abstract Subscribe to one of our other 19 science newsletters such as Mammary Cell News & ESC & iPSC News. | |
| |
REVIEWSMolecular Underpinnings Governing Genetic Complexity of ETS-Fusion-Negative Prostate Cancer Inter- and intra-patient molecular heterogeneity of primary and metastatic prostate cancer confers variable clinical outcome and poses a formidable challenge in disease management. The authors focus on the emerging molecular underpinnings driving key oncogenic aberrations and advancements in therapeutic strategies of this disease. [Trends Mol Med] Abstract Visit our reviews page to see a complete list of reviews in the prostate cell research field. | |
| |
INDUSTRY NEWSAnixa Biosciences, Inc. announced that it is partnering with the VA Maryland Health Care System’s Baltimore VA Medical Center and the Baltimore Research and Education Foundation, a non-profit affiliate, in its ongoing prostate cancer Cchekâ„¢ study. [Anixa Biosciences, Inc.] Press Release Salarius Pharmaceuticals, Inc. announced it has enrolled the first patient in a Phase I clinical study of the company’s lead compound, Seclidemstat, in patients with advanced solid tumors resistant to standard-of-care therapies. [Salarius Pharmaceuticals, Inc.] Press Release | |
| |
POLICY NEWSFormer UK Science Minister Returns as Brexit Government Assembles The prime minister shake-up sees a return to the Conservative government for Jo Johnson, the prime minister’s brother and a former minister for universities and science. Johnson, who was generally popular with scientists, is back as a minister straddling the Department for Business, Energy and Industrial Strategy — which oversees research — and the Department for Education. [Nature News] Editorial Indonesia’s Strict New Biopiracy Rules Could Stifle International Research Indonesia’s rich biodiversity and complex geology have lured scientists from abroad for centuries. But a law adopted by Indonesia’s parliament may convince some to go elsewhere. The legislation includes strict requirements on foreign scientists doing research in Indonesia, including the need to recruit local collaborators and a near-ban on exporting specimens, along with stiff sanctions, including jail time, for violators. [ScienceInsider] Editorial
| |
EVENTSNEW Keystone Symposia: Single Cell Biology: Pushing New Frontiers in the Life Sciences Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Scientific Communications Coordinator (STEMCELL Technologies Inc.) NEW Postdoctoral Scientist – Prostate Oncobiology (Cancer Research UK) Research Officer – Tumor Progression (Garvan Institute of Medical Research) Postdoctoral Researcher – Genitourinary Cancers (CCTI Columbia University) Senior Endowed Professorship – Cellular Principles & Evolution (Stony Brook University) Research Scientist – Prostate Cancer Progression & Resistance (MD Anderson Cancer Center) Postdoctoral Position – Prostate Biology (University of Washington) Postdoctoral Scientist – Prostate Organoids (Rutgers Cancer Institute of New Jersey) Research Lab Specialist – Tumor Microenvironment & Cell Behavior (University of Southern California) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Prostate Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|